Companies
HTL Biotechnology
HTL Biotechnology in Brittany (a more than 64,000 m² site) is a global leader in pharmaceutical-grade biopolymers, running fermentation through extraction and purification on a solvent-free route and inaugurating a new sterile hyaluronic-acid production line on 6 June 2025.
- Country
- France
Pharma-grade HA biopolymer
GMP / solvent-free
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| fibers-textiles | ✓ | ✓ | ✓ |
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Majority stake acquired by Montagu (2022) | htlbiotech.com |
| Capacity | Includes four independent production units for hyaluronic acid and polynucleotides; capacity increased by factor of 2.3 for hyaluronic acid with HTL4 unit | htlbiotech.com |
| Certification | ISO 13485, ISO 14001, and Halal certification | htlbiotech.com |
| Regulatory approval | Site periodically inspected by FDA and ANSM; complies with cGMP Part II for API manufacture | htlbiotech.com |
| Production site | Historic site in Javené, Brittany, France (over 64,000 m²); production unit in the United States; production unit under construction in Boston | htlbiotech.com |
| Headcount | Approximately 179 to 300 employees worldwide medium confidence | htlbiotech.com |
| Revenue | Reported as 100M turnover (2023 report), $27.8M (LinkedIn/CB Insights), or $44.2M (Growjo) medium confidence | htlbiotech.com · clodura.ai |
Independent sources: clodura.ai
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biosynthetic hyaluronic acid | specialty-fine-chem | Low | → |
| Recombinant collagen & gelatin | fibers-textiles | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.